« Previous
Next »
Seminars in Hematology
Volume 40, Issue 1
, Pages
72-78
, January 2003
Autografting in chronic myeloid leukemia
-
Duration of cytogenetic response after ASCT according to BCR-ABL/ABL ratio (A) 0.01 (23 patients) and (B) > 0.01 (27 patients) in the graft.
Duration of cytogenetic response after ASCT according to BCR-ABL/ABL ratio (A) 0.01 (23 patients) and (B) > 0.01 (27 patients) in the graft.
-
Autografting in 50 patients with ECP-CML: overall survival. Arrows indicate patients who relapsed after IFN-α and received imatinib. The other patients (+) are now alive receiving IFN-α therapy.
Autografting in 50 patients with ECP-CML: overall survival. Arrows indicate patients who relapsed after IFN-α and received imatinib. The other patients (+) are now alive receiving IFN-α therapy.
-
Flow chart of the protocol proposed by our team. HR, hematological remission; MCyR, major cytogenetic remission; NoCyR, no cytogenetic remission; HD, high-dose; Glivec (Novartis Pharmaceuticals, Hanov
Flow chart of the protocol proposed by our team. HR, hematological remission; MCyR, major cytogenetic remission; NoCyR, no cytogenetic remission; HD, high-dose; Glivec (Novartis Pharmaceuticals, Hanover, NJ), imatinib mesylate.
☆ Supported by “Un Taglio per la vita.”
☆☆ Address reprint requests to Angelo M. Carella, MD, IRCCS, Ospedale “Casa Sollievo della Sofferenza,” Department of Hematology/Oncology-Viale Cappuccini, 71013 San Giovanni Rotondo (FG), Italy.
PII: S0037-1963(03)70044-4
« Previous
Next »
Seminars in Hematology
Volume 40, Issue 1
, Pages
72-78
, January 2003
